Next-generation blood thinner from Bristol Myers Squibb, J&J fails key trial Milvexian, being closely watched as potential blockbuster, is being tested in two more late-stage studies

https://www.statnews.com/2025/11/14/milvexian-bristol-myers-johnson-and-johnson/